CDXS · Codexis, Inc.
$1.42
+0.06 (+4.51%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$148.38M
Shares
109.51M
Volume · Oct 5
894.35K
Avg daily vol (3M)
1.11M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.36
Open$1.39
Day$1.35–1.41
52W close$0.98–2.85
Avg vol 30d858K
Short int4.0M · 3.7% float · 5.7d
Short vol51%
Last earningsAug 11, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 5 wks
filed Aug 11, 2026
call held Aug 11, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$77.68M
Trailing 12 months
Net income (TTM)
−$30.72M
Trailing 12 months
Revenue growth YoY
-2.7%
Year over year
Operating margin
-35.6%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-8.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$14.04M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6.6%
Year over year · more shares
Price change (1Y)
-46.0%
Trailing year
Short interest
3.7%
Latest settlement · 5.7 days to cover
AI Brief
Q2 FY26 earnings call · Aug 11, 2026
Q2 FY26
TL;DR. Codexis reported Q2 2026 revenue of $14.9 million, reiterated its full-year $72–$76 million revenue guidance, and highlighted ECO Synthesis platform advances including stereoisomer control and single-nucleotide initiation, while completing a ~$25 million equity raise that extends cash runway through 2028.
Bullish
- + Company completed a ~$25 million equity raise, bringing pro forma cash to ~$80 million and extending runway through 2028.
- + Q2 product gross margin improved to 73%, driven by higher-margin new product launches, and full-year gross margin is now expected in the high 60% range.
- + Net loss narrowed to $12.0 million ($0.13/share) from $13.3 million ($0.16/share) year over year as R&D and SG&A both declined.
- + Biocatalysis business renewed growth trend with four product approvals and one label expansion in 2026 across 14 commercial products and 15 Phase II/III programs.
- + Company is in negotiations for a long-term commercial contract with the most advanced of three CDMO partners that have completed small-scale tech transfers.
Bearish
- − Cash, cash equivalents and short-term investments fell to $54.9 million at quarter-end from $78.2 million at year-end 2025 before the financing.
- − Achieving the back-half-weighted full-year revenue guidance of $72–$76 million requires a steep sequential step-up from H1 2026 revenue of $30.16 million.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−27%
below
Price vs 50-day avg
−8%
below
RSI (14)
41
neutral
MACD trend
Positive
52-week position
20%
mid-range
Momentum
relative strength
1-month return
−4%
trailing
6-month return
−41%
trailing
YTD return
−17%
this year
Relative strength
−53%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.68% of float · ▲ +4.6% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
148 holders — near 3-yr high, broad support
Squeeze score
53
elevated · 0–100
Fundamentals
Revenue growth
+32%
Y/Y
EPS growth
+44%
Y/Y
Free cash flow
$-23.8M
Balance sheet
$10.7M
net cash
Quant / Vol
risk profile
Volatility
86%
annualized · 1-yr
Max drawdown
−64%
past year
ATR
6.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 11, 2026
Total revenues
· full-year 2026
Initiated
$72M – $76M
prior FY $70.39M
midpoint +5.1% Y/Y
Guided vs delivered
· last 3 settled
Total revenue
2023
guided $63M – $68M
$70.14M
Beat +7.1%
Total revenues
2022
guided $135M – $141M
$138.59M
In line
Total revenues
full year 2021
guided $98M – $103M
$104.75M
Beat +4.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−27%
Bearish
Price vs 50-day avg
−8%
Bearish
RSI (14)
41
Neutral
MACD trend
Positive
Bullish
52-week position
20%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Accumulating
+10% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
3.68% of float · ▲ +4.6% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
148 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1
Now $1 · 20%
Range high $3
vs 200-day avg -27%
vs 50-day avg -8%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Product gross margin | 73% | the second quarter of 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CDXS
this stock
Codexis, Inc.
|
$148.38M | -16.6% | +32.3% | — | 3.7% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CDXS | +3.0% | -4.2% | -40.9% | -2.2% | -16.6% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +3.3% | -3.8% | -53.1% | -3.1% | -29.4% |